Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Erasmus Medical Center
With
Dutch Pancreatic Cancer Group
Dutch Cancer Society
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically (Bethesda 5 or 6) confirmed pancreatic ductal adenocarcinoma.
Resectable tumor according to Dutch Pancreatic Cancer Group criteria: no arterial contact and venous contact with the superior mesenteric vein or portal vein of 90 degrees or less
No evidence for metastatic disease
WHO performance status of 0 or 1
Ability to undergo surgery and mFOLFIRINOX chemotherapy
Leucocytes (WBC) ≥ 3.0 x 10\^9/L
Platelets ≥ 100 x 10\^9/L
Hemoglobin ≥ 6.0 mmol/l
Renal function: eGFR ≥ 40 ml/min
Age ≥ 18 years
Written informed consent
You may not be if
Prior radiotherapy, chemotherapy, or surgery for pancreatic cancer.
Prior chemotherapy precluding mFOLFIRINOX.
Previous malignancy (excluding non-melanoma skin cancer, pancreatic neuroendocrine tumor (pNET) \<2cm, and gastrointestinal stromal tumor (GIST) \<2cm), unless no evidence of disease and diagnosed more than 3 years before diagnosis of pancreatic cancer, or with a life expectancy of more than 5 years from date of inclusion.
Pregnancy or lactation.
Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Clareo Health | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
